<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; follow</title>
	<atom:link href="http://www.tapanray.in/tag/follow/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Against Pharma Marketing Malpractices: A Gutsy Step</title>
		<link>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=against-pharma-marketing-malpractices-a-gutsy-step</link>
		<comments>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/#comments</comments>
		<pubDate>Mon, 22 Feb 2016 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[58th]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Clinton]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[conflit]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[dollars for doc]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[follow]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Gutsy]]></category>
		<category><![CDATA[Hilary]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharnaceuticals]]></category>
		<category><![CDATA[Physician Payments Sunshine Act]]></category>
		<category><![CDATA[ProPublica]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Voluntary]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7447</guid>
		<description><![CDATA[January 7, 2016 edition of ‘The Financial Times (FT)’ reported that responding to escalating pressure on the drug industry, related to its ‘Conflict of Interest’ with the doctors and other related professionals, GlaxoSmithKline (GSK) has decided taking a very unorthodox &#8230; <a href="http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/against-pharma-marketing-malpractices-a-gutsy-step/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Should India follow the US way to regulate all types of lobbying in the country?</title>
		<link>http://www.tapanray.in/should-india-follow-the-us-way-to-regulate-all-types-of-lobbying-in-the-country/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=should-india-follow-the-us-way-to-regulate-all-types-of-lobbying-in-the-country</link>
		<comments>http://www.tapanray.in/should-india-follow-the-us-way-to-regulate-all-types-of-lobbying-in-the-country/#comments</comments>
		<pubDate>Mon, 31 Oct 2011 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[follow]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[radia]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulate]]></category>
		<category><![CDATA[scam]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[types]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=181</guid>
		<description><![CDATA[Currently, India is one of the fastest-growing economies of the world along with China. Even during the recent global financial meltdown process both India and China could register a very impressive average GDP growth of around 7% consistently during the &#8230; <a href="http://www.tapanray.in/should-india-follow-the-us-way-to-regulate-all-types-of-lobbying-in-the-country/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/should-india-follow-the-us-way-to-regulate-all-types-of-lobbying-in-the-country/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
